{"id":"W2703678370","doi":"10.1200/jco.2016.34.15_suppl.101","title":"A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Agonist; Internal medicine; Antibody; Pharmacokinetics; Immunotherapy; Adverse effect; Oncology; Pharmacology; Cancer; Pembrolizumab; Immunology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001911869,0.0001064433,0.0009201232,0.00006091683,0.00004694613,0.000005309542,0.0001300813,0.0001130527,0.00002293173],"category_scores_gemma":[0.0009994562,0.00003730412,0.0001756624,0.0001495814,0.000548906,0.00009548642,0.00004304954,0.0003654108,6.113384e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001151078,"about_ca_system_score_gemma":0.0004924848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003285499,"about_ca_topic_score_gemma":0.0001558373,"domain_scores_codex":[0.9971052,0.0005270455,0.001759829,0.0001321475,0.0003388421,0.0001368893],"domain_scores_gemma":[0.9966643,0.001110521,0.001687864,0.0002032403,0.0002504793,0.00008360052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2977633,0.009745074,0.2397961,0.00001365272,0.0003192,0.00003482676,0.0006453025,0.000002909897,0.0005957115,0.00001249979,0.0001601009,0.4509113],"study_design_scores_gemma":[0.1915985,0.03551963,0.7704545,0.0002496408,0.0001462535,0.00002469652,0.0002579402,0.00001061996,0.0001219526,0.00005519261,0.001511568,0.00004941255],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934447,0.0001358582,0.000009453974,0.00519786,0.0004364775,0.0006417074,0.000003014312,0.000002376679,0.0001284865],"genre_scores_gemma":[0.9989686,0.0001549699,0.00006216265,0.0005381498,0.0001994073,0.000006759848,3.408606e-7,0.000009605805,0.00005998676],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5306584,"threshold_uncertainty_score":0.2022467,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03716742583024048,"score_gpt":0.4133332806145038,"score_spread":0.3761658547842633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}